Flagship Pioneering: Novo Nordisk Enters Into Research Collaborations With Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases
January 05, 2024
January 05, 2024
CAMBRIDGE, Massachusetts, Jan. 5 -- Flagship Pioneering, a bioplatform innovation company, issued the following news release on Jan. 4, 2024:
Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity . . .
Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity . . .